1.四川大学华西医院内分泌代谢科,垂体瘤及相关疾病诊疗中心,成都 610041
2.郑州大学附属第一医院健康管理中心成都 610041
Received:31 May 2023,
Revised:2023-08-13,
Accepted:28 August 2023,
Published:28 September 2023
移动端阅览
张滔,秦迁,谭惠文.垂体多激素腺瘤病例报道:单中心研究[J].重庆医科大学学报,2023,48(9):1107-1113.
Zhang Tao,Qin Qian,Tan Huiwen.A case report of pituitary multi-hormone adenoma:a single center study[J].Journal of Chongqing Medical University,2023,48(9):1107-1113.
张滔,秦迁,谭惠文.垂体多激素腺瘤病例报道:单中心研究[J].重庆医科大学学报,2023,48(9):1107-1113. DOI: 10.13406/j.cnki.cyxb.003320.
Zhang Tao,Qin Qian,Tan Huiwen.A case report of pituitary multi-hormone adenoma:a single center study[J].Journal of Chongqing Medical University,2023,48(9):1107-1113. DOI: 10.13406/j.cnki.cyxb.003320.
目的
2
加强对于同时产生生长激素(growth hormone,GH)和促甲状腺激素(thyroidstimulatinghormone,TSH)的垂体腺瘤的认识,防止误诊、漏诊、延诊,并探讨其治疗。
方法
2
回顾性分析5例在四川大学华西医院确诊为垂体GH+TSH 瘤患者的临床表现、激素生化检查、影像学检查、治疗方式以及预后情况。
结果
2
①5例GH+TSH瘤占四川大学华西医院同期诊断的垂体瘤的2.9%(4/172);其中2例患者病理提示:TSH+GH+PRL为阳性,另外3例病理提示:TSH+GH为阳性。②鞍区MRI扫描5例均为大腺瘤(直径≥1 cm),无小腺瘤。③术前4例患者(病例2、3、4、5)GH基线水平明显升高(随机值>2.5 ng/mL),其中2例不被高糖抑制,2例患者未行高糖抑制实验;病例1因既往已多次反复治疗,目前GH已完全生化缓解。4例患者(病例1、2、4、5)FT4升高且TSH不被抑制,其中2例患者存在甲状腺毒症;2例患者性腺轴水平下降。5例患者中4例为经鼻内镜鞍区占位切除术,其术后大部分GH、TSH、FT4均明显下降(其中2例恢复到正常范围,另有1例GH水平有下降,但未完全缓解,TSH、FT4水平恢复正常,另1例GH、TSH、FT4均无明显变化)。余病例1既往伽玛刀治疗后给予药物治疗,第3次复发采用手术治疗后GH水平缓解,但TSH、FT4仍未得到缓解;术后性激素结果提示:2例患者性腺功能减退患者性腺功能未立即恢复正常。5例患者术前、术后垂体-肾上腺轴功能均正常。
结论
2
垂体GH+TSH混合瘤临床发病率低,起病隐匿,多因甲状腺毒症而被误诊,易错过最佳治疗时机,手术治疗仍是该病的一线治疗方式。
Objective
2
To strengthen the understanding of pituitary adenoma that produces growth hormone(GH) and thyroidstimulatinghormone(TSH). And more,to prevent misdiagnosis,missed diagnosis and delayed diagnosis,and to explore its treatment.
Methods
2
The clinical manifestations,hormone biochemical examination,imaging examination,treatment and prognosis of 5 patients with pituitary GH+TSH adenoma diagnosed in West China Hospital were analyzed retrospectively.
Results
2
①5 cases of GH+TSH tumors accounted for 2.9%(4 /172) of pituitary tumors diagnosed at the same time in west china hospital. Pathological findings of 2 patients showed that TSH,GH and PRL were all positive,and pathological findings of 3 patients showed that TSH and GH were all positive. ②MRI scan of sellar region showed that 5 cases were large adenomas(diameter > 1cm) and no small adenomas. ③Before operation,the baseline level of GH in 4 patients(cases 2,3,4 and 5) increased significantly(random value > 2.5ng/mL),of which 2 patients were not inhibited by high glucose,and 2 patients were not subjected to high glucose inhibition experiment; Case 1 has been repeatedly treated in the past,and now GH has completely biochemical remission. Four patients(cases 1,2,4 and 5) had elevated 5)FT4 and TSH was not inhibited,among which 2 patients had thyrotoxicosis. The level of gonadal axis decreased in 2 patients. Among the 5 patients,4 cases underwent space-occupying resection in the sellar region through nasal endoscope,and most of their GH,TSH and FT4 decreased significantly after operation(2 cases recovered to the normal range,while the GH level in another case decreased,but not completely relieved,and the TSH and FT4 levels returned to normal,while the GH,TSH and FT4 in the other case did not change significantly). The remaining case 1 was treated with gamma knife first,then with drug,and the GH level was relieved after the third recurrence was treated with surgery,but TSH and FT4 were still not relieved. The results of postoperative sex hormones suggest that the gonadal function of 2 patients with hypogonadism did not return to normal immediately. The function of pituitary-adrenal axis was normal in 5 patients before and after operation.
Conclusion
2
The clinical incidence of pituitary GH+TSH mixed tumor is low,the onset is insidious,and it is often misdiagnosed because of thyrotoxicosis,which is easy to miss the best treatment opportunity. Surgery is still the first-line treatment for this disease.
Mori R , Inoshita N , Takahashi-Fujigasaki J , et al . Clinicopathological Features of Growth Hormone-Producing Pituitary Adenomas in 242 Acromegaly Patients:Classification according to Hormone Production and Cytokeratin Distribution [J ] . ISRN Endocrinol , 2013 , 2013 : 723432 .
Colao A , Grasso LFS , Giustina A , et al . Acromegaly [J ] . Nat Rev Dis Primers , 2019 ,( 1 ): 20 .
段炼 , 王诗蕊 , 朱惠娟 , 等 . 《中国肢端肥大症诊治共识(2021版)》更新要点解读 [J ] . 中华医学杂志 , 2021 , 101 ( 27 ): 2111 - 2114 .
Duan L , Wang SR , Zhu HJ , et al . Updated key points of Chinese Consensus for the Diagnosis and Treatment of Acromegaly(2021 edition) [J ] . National Medical Journal of China , 2021 , 101 ( 27 ): 2111 - 2114 .
李冉 , 段炼 , 潘慧 , 等 . 奥曲肽敏感试验预测长效生长抑素受体配体治疗垂体GH腺瘤的疗效 [J ] . 中华内分泌代谢杂志 , 2022 , 38 ( 4 ): 288 - 293 .
LI R , Duan L , Pan H , et al . Value of octreotide suppression test in predicting the efficacy of long-acting somatostatin receptor ligands in pituitary GH adenomas [J ] . Chinese Journal of Endocrinology and Metabolism , 2022 , 38 ( 4 ): 288 - 293 .
中国垂体腺瘤协作组 . 中国垂体促甲状腺激素腺瘤诊治专家共识(2017) [J ] . 中华医学杂志 , 2017 , 97 ( 15 ): 1128 - 1131 .
China Pituitary adenoma Collaboration Group . China expert consensus of diagnosis and treatment of pituitary thyroid stimulating hormone adenoma(2017) [J ] . Chinese journal of medicine , 2017 , 97 ( 15 ): 1128 - 1131 .
Liu J , Yang YM , Duan L , et al . Characteristics and response cutoff of octreotide suppression test in thyrotrophin(TSH)-secreting pituitary adenomas [J ] . Clin Endocrinol , 2023 , 99 ( 3 ): 306 - 314 .
中华医学会内分泌学分会 . 肢端肥大症诊治中国专家共识(2020版) [J ] . 中华内分泌代谢杂志 , 2020 , 36 ( 9 ): 751 - 760 .
Chinese Society of Endocrinology . China expert consensus of diagnosis and treatment of acromegaly(2020 edition) [J ] . Chinese endocrine metabolism , 2020 , 4 ( 9 ): 751 - 760 .
徐剑 , 张春芳 , 范虹 , 等 . 垂体促甲状腺激素混合型腺瘤的临床特点和治疗 [J ] . 中国医师进修杂志 , 2020 , 43 ( 7 ): 655 - 658 .
Xu J , Zhang CF , Fang H , et al . Pituitary thyrotropin mixed adenoma of the clinical characteristics and treatment [J ] . Chinese journal of doctor education ,the lancet 2020 ( 7 ): 655 - 658 .
卓勤俭 , 程雷鸣 . 混合性垂体促甲状腺激素、生长激素、促性腺激素腺瘤致垂体甲状腺功能亢进症一例 [J ] . 中华临床医师杂志 (电子版), 2011 , 5 ( 12 ): 3684 - 3689 .
Zhuo QJ , Cheng LM . Pituitary hyperthyroidism caused by mixed pituitary thyrotropin,growth hormone and gonadotropin adenoma [J ] . The Chinese journal of clinical physicians(electronic version) , 2011 , 5 ( 12 ): 3684 - 3689 .
姜艳 , 顾锋 , 朱惠娟 , 等 . 分泌促甲状腺素及生长激素的垂体混合瘤临床特点及诊疗分析 [J ] . 中国实用内科杂志 , 2016 , 36 ( 7 ): 567 - 569 .
Jiang Y , Gu F , Zhu HJ , et al . Clinical characteristics of pituitary adenoma co-secreting thyroid stimulating hormone and growth hormone and analysis of its diagnosis and treatment . Chinese Journal of Practical Internal Medicine , 2016 , 36 ( 7 ): 567 - 569 .
周芬 , 张木勋 , 雷霆 . 120例垂体生长激素腺瘤及多激素腺瘤的临床和病理学特点分析 [J ] . 中国临床神经外科杂志 , 2010 , 15 ( 2 ): 92 - 94 .
Zhou F , Zhang MX , Lei T . Analysis of clinical and pathological characteristics of GH-secreling pituitary adenomas and mixed pituitary adenomas in 120 patients [J ] . Chinese Journal of clinical neurosurgery , 2010 , 15 ( 2 ): 92 - 94 .
刘冬戈 , 臧旭 , 薛辉 , 等 . 垂体多激素腺瘤的临床病理分析及免疫电镜观察 [J ] . 中华神经精神科杂志 , 1994 , 27 ( 4 ): 232 - 235 .
Liu DG , Zang X , Xue H , et al . Clinical pathological analysis and immunoelectron microscopy observation of pituitary polyhormone adenoma [J ] . Chinese Journal of Neuropsychiatry , 1994 , 27 ( 4 ): 232 - 235 .
Wang P , Wang T , Yang Y , et al . Detection of programmed death ligand 1 protein and CD8 + lymphocyte infiltration in plurihormonal pituitary adenomas:A case report and review of the literatures [J ] . Medicine(Baltimore) , 2017 , 96 ( 49 ): e9056 .
Lloyd RV , Chandler WF , Kovacs K , et al . Ectopic pituitary adenomas with normal anterior pituitary glands [J ] . Am J Surg Pathol , 1986 , 10 ( 8 ): 546 - 552 .
Mohammed S , Syro LV , Scheithauer BW , et al . Pituitary adenoma with peliosis:a report of two cases [J ] . Endocr Pathol , 2009 , 20 ( 1 ): 41 - 45 .
Roca E , Mattogno PP , Porcelli T , et al . Plurihormonal ACTH-GH Pituitary Adenoma:Case Report and Systematic Literature Review [J ] . World Neurosurg , 2018 , 114 : e158 - e164 .
Luk CT , Kovacs K , Rotondo F , et al . Plurihormonal pituitary adenoma immunoreactive for thyroid-stimulating hormone,growth hormone,follicle-stimulating hormone,and prolactin [J ] . Endocr Pract , 2012 , 18 ( 5 ): e121 - e126 .
Rasul FT , Jaunmuktane Z , Khan AA , Phadke R , Powell M . Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone(ACTH) and growth hormone(GH) secretion:a report of two cases and review of the literature [J ] . Acta Neurochir(Wien) , 2014 , 156 ( 1 ): 141 - 146 .
Tordjman KM , Greenman Y , Ram Z , et al . Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages,with Synchronous Collision Corticotroph Tumor:a Possible Stem Cell Phenomenon [J ] . Endocr Pathol , 2019 , 30 ( 1 ): 74 - 80 .
滕晓春 , 金婷 , 王冉冉 , 等 . 一例TRβ基因P453 T突变所致的甲状腺激素抵抗综合征合并垂体TSH微腺瘤的病例报告 [J ] . 中华内分泌代谢杂志 , 2016 ( 1 ): 19 - 23 .
Teng XC , Jin T , Wang RR , et al . One case of a thyrotropin-secreting microadenoma and resistance to thyroid hormone with P453T mutation in TRβgene [J ] . Chinese Journal of Endocrinology and Metabolism , 2016 ( 1 ): 19 - 23 .
巩纯秀 , 谷奕 . 甲状腺激素不敏感综合征的诊断与治疗 [J ] . 中华实用儿科临床杂志 , 2019 , 34 ( 8 ): 571 - 574 .
Gong CX , GU Y . Diagnosis and treatment of resistance to the thyroid hormone [J ] . Chinese Journal of Applied Clinical Pediatrics , 2019 , 34 ( 8 ): 571 - 574 .
Reikvam H , Tiu RV . Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera [J ] . Leukemia , 2012 , 26 ( 4 ): 563 - 571 .
Beck-Peccoz P , Giavoli C , Lania A . A 2019 update on TSH-secreting pituitary adenomas [J ] . J Endocrinol Invest , 2019 , 42 ( 12 ): 1401 - 1406 .
Nazato DM , Abucham J . Diagnosis and treatment of TSH-secreting adenomas:review of a longtime experience in a reference center [J ] . J Endocrinol Invest , 2018 , 41 ( 4 ): 447 - 454 .
0
Views
12
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621
